\contentsline {chapter}{Glossary}{xi}{section*.4}
\contentsline {chapter}{Acronyms}{xii}{section*.6}
\contentsline {chapter}{\numberline {1}Introduction}{1}{chapter.1}
\contentsline {section}{\numberline {1.1}Cancer Research in the Post-Genomic Era}{1}{section.1.1}
\contentsline {subsection}{\numberline {1.1.1}Cancer as a Global Health Concern}{2}{subsection.1.1.1}
\contentsline {subsubsection}{\numberline {1.1.1.1}The Genetics and Molecular Biology of Cancers}{3}{subsubsection.1.1.1.1}
\contentsline {subsection}{\numberline {1.1.2}The Human Genome Revolution}{6}{subsection.1.1.2}
\contentsline {subsubsection}{\numberline {1.1.2.1}The First Human Genome Sequence}{6}{subsubsection.1.1.2.1}
\contentsline {subsubsection}{\numberline {1.1.2.2}Impact of Genomics}{7}{subsubsection.1.1.2.2}
\contentsline {subsection}{\numberline {1.1.3}Technologies to Enable Genetics Research}{7}{subsection.1.1.3}
\contentsline {subsubsection}{\numberline {1.1.3.1}DNA Sequencing and Genotyping Technologies}{7}{subsubsection.1.1.3.1}
\contentsline {subsubsection}{\numberline {1.1.3.2}Microarrays and Quantitative Technologies}{8}{subsubsection.1.1.3.2}
\contentsline {subsubsection}{\numberline {1.1.3.3}Massively Parallel ``Next Generation'' Sequencing}{9}{subsubsection.1.1.3.3}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.1}Molecular Profiling with Genomics Technology}{11}{subsubsubsection.1.1.3.3.1}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.2}Sequencing Technologies}{11}{subsubsubsection.1.1.3.3.2}
\contentsline {subsubsection}{\numberline {1.1.3.4}Bioinformatics as Interdisciplinary Genomic Analysis}{12}{subsubsection.1.1.3.4}
\contentsline {subsection}{\numberline {1.1.4}Follow-up Large-Scale Genomics Projects}{13}{subsection.1.1.4}
\contentsline {subsection}{\numberline {1.1.5}Cancer Genomes}{14}{subsection.1.1.5}
\contentsline {subsubsection}{\numberline {1.1.5.1}The Cancer Genome Atlas Project}{15}{subsubsection.1.1.5.1}
\contentsline {subsubsubsection}{\numberline {1.1.5.1.1}Findings from Cancer Genomes}{15}{subsubsubsection.1.1.5.1.1}
\contentsline {subsubsubsection}{\numberline {1.1.5.1.2}Genomic Comparisons Across Cancer Tissues}{17}{subsubsubsection.1.1.5.1.2}
\contentsline {subsubsubsection}{\numberline {1.1.5.1.3}Cancer Genomic Data Resources}{18}{subsubsubsection.1.1.5.1.3}
\contentsline {subsection}{\numberline {1.1.6}Genomic Cancer Medicine}{18}{subsection.1.1.6}
\contentsline {subsubsection}{\numberline {1.1.6.1}Cancer Genes and Driver Mutations}{18}{subsubsection.1.1.6.1}
\contentsline {subsubsection}{\numberline {1.1.6.2}Personalised or Precision Cancer Medicine}{19}{subsubsection.1.1.6.2}
\contentsline {subsubsubsection}{\numberline {1.1.6.2.1}Molecular Diagnostics and Pan-Cancer Medicine}{20}{subsubsubsection.1.1.6.2.1}
\contentsline {subsubsection}{\numberline {1.1.6.3}Targeted Therapeutics and Pharmacogenomics}{21}{subsubsection.1.1.6.3}
\contentsline {subsubsubsection}{\numberline {1.1.6.3.1}Targeting Oncogenic Driver Mutations}{21}{subsubsubsection.1.1.6.3.1}
\contentsline {subsubsection}{\numberline {1.1.6.4}Systems and Network Biology}{22}{subsubsection.1.1.6.4}
\contentsline {subsubsubsection}{\numberline {1.1.6.4.1} Network Medicine, and Polypharmacology}{24}{subsubsubsection.1.1.6.4.1}
\contentsline {section}{\numberline {1.2}A Synthetic Lethal Approach to Cancer Medicine}{25}{section.1.2}
\contentsline {subsection}{\numberline {1.2.1}Synthetic Lethal Genetic Interactions}{26}{subsection.1.2.1}
\contentsline {subsection}{\numberline {1.2.2}Synthetic Lethal Concepts in Genetics}{26}{subsection.1.2.2}
\contentsline {subsection}{\numberline {1.2.3}Studies of Synthetic Lethality}{27}{subsection.1.2.3}
\contentsline {subsubsection}{\numberline {1.2.3.1}Synthetic Lethal Pathways and Networks}{28}{subsubsection.1.2.3.1}
\contentsline {subsubsubsection}{\numberline {1.2.3.1.1}Evolution of Synthetic Lethality}{29}{subsubsubsection.1.2.3.1.1}
\contentsline {subsection}{\numberline {1.2.4}Synthetic Lethal Concepts in Cancer}{29}{subsection.1.2.4}
\contentsline {subsection}{\numberline {1.2.5}Clinical Impact of Synthetic Lethality in Cancer}{31}{subsection.1.2.5}
\contentsline {subsection}{\numberline {1.2.6}High{}-throughput Screening for Synthetic Lethality}{33}{subsection.1.2.6}
\contentsline {subsubsection}{\numberline {1.2.6.1}Synthetic Lethal Screens}{34}{subsubsection.1.2.6.1}
\contentsline {subsection}{\numberline {1.2.7}Computational Prediction of Synthetic Lethality}{37}{subsection.1.2.7}
\contentsline {subsubsection}{\numberline {1.2.7.1}Bioinformatics Approaches to Genetic Interactions}{37}{subsubsection.1.2.7.1}
\contentsline {subsubsection}{\numberline {1.2.7.2}Comparative Genomics}{38}{subsubsection.1.2.7.2}
\contentsline {subsubsection}{\numberline {1.2.7.3}Analysis and Modelling of Protein Data}{41}{subsubsection.1.2.7.3}
\contentsline {subsubsection}{\numberline {1.2.7.4}Differential Gene Expression}{43}{subsubsection.1.2.7.4}
\contentsline {subsubsection}{\numberline {1.2.7.5}Data Mining and Machine Learning}{44}{subsubsection.1.2.7.5}
\contentsline {subsubsection}{\numberline {1.2.7.6}Bimodality}{47}{subsubsection.1.2.7.6}
\contentsline {subsubsection}{\numberline {1.2.7.7}Rationale for Further Development}{48}{subsubsection.1.2.7.7}
\contentsline {section}{\numberline {1.3}E-cadherin as a Synthetic Lethal Target}{48}{section.1.3}
\contentsline {subsection}{\numberline {1.3.1}The \textit {CDH1} gene and it's Biological Functions}{48}{subsection.1.3.1}
\contentsline {subsubsection}{\numberline {1.3.1.1}Cytoskeleton}{49}{subsubsection.1.3.1.1}
\contentsline {subsubsection}{\numberline {1.3.1.2}Extracellular and Tumour Micro-Environment}{49}{subsubsection.1.3.1.2}
\contentsline {subsubsection}{\numberline {1.3.1.3}Cell-Cell Adhesion and Signalling}{49}{subsubsection.1.3.1.3}
\contentsline {subsection}{\numberline {1.3.2}\textit {CDH1} as a Tumour (and Invasion) Suppressor}{50}{subsection.1.3.2}
\contentsline {subsubsection}{\numberline {1.3.2.1}Breast Cancers and Invasion}{50}{subsubsection.1.3.2.1}
\contentsline {subsection}{\numberline {1.3.3}Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer}{50}{subsection.1.3.3}
\contentsline {subsection}{\numberline {1.3.4}Somatic Mutations}{52}{subsection.1.3.4}
\contentsline {subsubsection}{\numberline {1.3.4.1}Mutation Rate}{52}{subsubsection.1.3.4.1}
\contentsline {subsubsection}{\numberline {1.3.4.2}Co-occurring Mutations}{52}{subsubsection.1.3.4.2}
\contentsline {subsection}{\numberline {1.3.5}Models of \textit {CDH1} loss in cell lines}{53}{subsection.1.3.5}
\contentsline {section}{\numberline {1.4}Summary and Research Direction of Thesis}{54}{section.1.4}
\contentsline {chapter}{\numberline {2}Methods and Resources}{75}{chapter.2}
\contentsline {section}{\numberline {2.1}Bioinformatics Resources for Genomics Research}{75}{section.2.1}
\contentsline {subsection}{\numberline {2.1.1}Public Data and Software Packages}{75}{subsection.2.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.1}Cancer Genome Atlas Data}{76}{subsubsection.2.1.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.2}Reactome and Annotation Data}{77}{subsubsection.2.1.1.2}
\contentsline {section}{\numberline {2.2}Data Handling}{78}{section.2.2}
\contentsline {subsection}{\numberline {2.2.1}Normalisation}{78}{subsection.2.2.1}
\contentsline {subsection}{\numberline {2.2.2}Sample Triage}{78}{subsection.2.2.2}
\contentsline {subsection}{\numberline {2.2.3}Metagenes and the Singular Value Decomposition}{80}{subsection.2.2.3}
\contentsline {subsubsection}{\numberline {2.2.3.1}Candidate Triage and Integration with Screen Data}{80}{subsubsection.2.2.3.1}
\contentsline {section}{\numberline {2.3}Techniques}{81}{section.2.3}
\contentsline {subsection}{\numberline {2.3.1}Statistical Procedures and Tests}{81}{subsection.2.3.1}
\contentsline {subsection}{\numberline {2.3.2}Gene Set Over-representation Analysis}{82}{subsection.2.3.2}
\contentsline {subsection}{\numberline {2.3.3}Clustering}{83}{subsection.2.3.3}
\contentsline {subsection}{\numberline {2.3.4}Heatmap}{83}{subsection.2.3.4}
\contentsline {subsection}{\numberline {2.3.5}Modeling and Simulations}{83}{subsection.2.3.5}
\contentsline {subsubsection}{\numberline {2.3.5.1}Receiver Operating Characteristic (Performance)}{84}{subsubsection.2.3.5.1}
\contentsline {subsection}{\numberline {2.3.6}Resampling Analysis}{85}{subsection.2.3.6}
\contentsline {section}{\numberline {2.4}Pathway Structure Methods}{86}{section.2.4}
\contentsline {subsection}{\numberline {2.4.1}Network and Graph Analysis}{86}{subsection.2.4.1}
\contentsline {subsection}{\numberline {2.4.2}Sourcing Graph Structure Data}{87}{subsection.2.4.2}
\contentsline {subsection}{\numberline {2.4.3}Constructing Pathway Subgraphs}{87}{subsection.2.4.3}
\contentsline {subsection}{\numberline {2.4.4}Network Analysis Metrics}{87}{subsection.2.4.4}
\contentsline {section}{\numberline {2.5}Implementation}{88}{section.2.5}
\contentsline {subsection}{\numberline {2.5.1}Computational Resources and Linux Utilities}{88}{subsection.2.5.1}
\contentsline {subsection}{\numberline {2.5.2}R Language and Packages}{90}{subsection.2.5.2}
\contentsline {subsection}{\numberline {2.5.3}High Performance and Parallel Computing}{92}{subsection.2.5.3}
\contentsline {chapter}{\numberline {3}Methods Developed During Thesis}{94}{chapter.3}
\contentsline {section}{\numberline {3.1}A Synthetic Lethal Detection Methodology}{94}{section.3.1}
\contentsline {section}{\numberline {3.2}Synthetic Lethal Simulation and Modelling}{97}{section.3.2}
\contentsline {subsection}{\numberline {3.2.1}A Model of Synthetic Lethality in Expression Data}{97}{subsection.3.2.1}
\contentsline {subsection}{\numberline {3.2.2}Simulation Procedure}{101}{subsection.3.2.2}
\contentsline {section}{\numberline {3.3}Detecting Simulated Synthetic Lethal Partners}{104}{section.3.3}
\contentsline {subsection}{\numberline {3.3.1}Binomial Simulation of Synthetic lethality}{104}{subsection.3.3.1}
\contentsline {subsection}{\numberline {3.3.2}Multivariate Normal Simulation of Synthetic lethality}{106}{subsection.3.3.2}
\contentsline {subsubsection}{\numberline {3.3.2.1}Multivariate Normal Simulation with Correlated Genes}{109}{subsubsection.3.3.2.1}
\contentsline {subsubsection}{\numberline {3.3.2.2}Specificity with Query-Correlated Pathways}{116}{subsubsection.3.3.2.2}
\contentsline {subsubsubsection}{\numberline {3.3.2.2.1}Importance of Directional Testing}{116}{subsubsubsection.3.3.2.2.1}
\contentsline {section}{\numberline {3.4}Graph Structure Methods}{118}{section.3.4}
\contentsline {subsection}{\numberline {3.4.1}Upstream and Downstream Gene Detection}{118}{subsection.3.4.1}
\contentsline {subsubsection}{\numberline {3.4.1.1}Permutation Analysis for Statistical Significance}{119}{subsubsection.3.4.1.1}
\contentsline {subsubsection}{\numberline {3.4.1.2}Hierarchy Based on Biological Context}{120}{subsubsection.3.4.1.2}
\contentsline {subsection}{\numberline {3.4.2}Simulating Gene Expression from Graph Structures}{121}{subsection.3.4.2}
\contentsline {section}{\numberline {3.5}Customised Functions and Packages Developed}{125}{section.3.5}
\contentsline {subsection}{\numberline {3.5.1}Synthetic Lethal Interaction Prediction Tool}{125}{subsection.3.5.1}
\contentsline {subsection}{\numberline {3.5.2}Data Visualisation}{126}{subsection.3.5.2}
\contentsline {subsection}{\numberline {3.5.3}Extensions to the iGraph Package}{128}{subsection.3.5.3}
\contentsline {subsubsection}{\numberline {3.5.3.1}Sampling Simulated Data from Graph Structures}{128}{subsubsection.3.5.3.1}
\contentsline {subsubsection}{\numberline {3.5.3.2}Plotting Directed Graph Structures}{128}{subsubsection.3.5.3.2}
\contentsline {subsubsection}{\numberline {3.5.3.3}Computing Information Centrality}{129}{subsubsection.3.5.3.3}
\contentsline {subsubsection}{\numberline {3.5.3.4}Testing Pathway Structure with Permutation Testing}{129}{subsubsection.3.5.3.4}
\contentsline {subsubsection}{\numberline {3.5.3.5}Metapackage to Install iGraph Functions}{130}{subsubsection.3.5.3.5}
\contentsline {chapter}{\numberline {4}Synthetic Lethal Analysis of Gene Expression Data}{131}{chapter.4}
\contentsline {section}{\numberline {4.1}Synthetic lethal genes in breast cancer}{132}{section.4.1}
\contentsline {subsection}{\numberline {4.1.1}Synthetic lethal pathways in breast cancer}{134}{subsection.4.1.1}
\contentsline {subsection}{\numberline {4.1.2}Expression profiles of synthetic lethal partners}{135}{subsection.4.1.2}
\contentsline {subsubsection}{\numberline {4.1.2.1}Subgroup pathway analysis}{138}{subsubsection.4.1.2.1}
\contentsline {section}{\numberline {4.2}Comparison of synthetic lethal gene candidates}{141}{section.4.2}
\contentsline {subsection}{\numberline {4.2.1}Comparison with siRNA screen candidates}{141}{subsection.4.2.1}
\contentsline {subsubsection}{\numberline {4.2.1.1}Comparison with correlation}{142}{subsubsection.4.2.1.1}
\contentsline {subsubsection}{\numberline {4.2.1.2}Comparison with viability}{143}{subsubsection.4.2.1.2}
\contentsline {subsubsection}{\numberline {4.2.1.3}Comparison with secondary siRNA screen candidates}{147}{subsubsection.4.2.1.3}
\contentsline {subsubsection}{\numberline {4.2.1.4}Comparison of screen at pathway level}{147}{subsubsection.4.2.1.4}
\contentsline {subsubsubsection}{\numberline {4.2.1.4.1}Resampling of genes for pathway enrichment}{149}{subsubsubsection.4.2.1.4.1}
\contentsline {section}{\numberline {4.3}Metagene Analysis}{155}{section.4.3}
\contentsline {subsection}{\numberline {4.3.1}Pathway expression}{155}{subsection.4.3.1}
\contentsline {subsection}{\numberline {4.3.2}Somatic mutation}{158}{subsection.4.3.2}
\contentsline {subsection}{\numberline {4.3.3}Mutation locus}{159}{subsection.4.3.3}
\contentsline {subsection}{\numberline {4.3.4}Synthetic lethal metagenes}{161}{subsection.4.3.4}
\contentsline {section}{\numberline {4.4}Replication in stomach cancer}{162}{section.4.4}
\contentsline {subsection}{\numberline {4.4.1}Synthetic Lethal Genes and Pathways}{163}{subsection.4.4.1}
\contentsline {subsection}{\numberline {4.4.2}Synthetic Lethal Expression Profiles}{165}{subsection.4.4.2}
\contentsline {subsection}{\numberline {4.4.3}Comparison to Primary Screen}{167}{subsection.4.4.3}
\contentsline {subsubsection}{\numberline {4.4.3.1}Resampling Analysis}{168}{subsubsection.4.4.3.1}
\contentsline {subsection}{\numberline {4.4.4}Metagene Analysis}{168}{subsection.4.4.4}
\contentsline {section}{\numberline {4.5}Global Synthetic Lethality}{169}{section.4.5}
\contentsline {subsection}{\numberline {4.5.1}Hub Genes}{170}{subsection.4.5.1}
\contentsline {subsection}{\numberline {4.5.2}Hub Pathways}{172}{subsection.4.5.2}
\contentsline {section}{\numberline {4.6}Replication in cell line encyclopaedia}{173}{section.4.6}
\contentsline {section}{\numberline {4.7}Discussion}{175}{section.4.7}
\contentsline {subsection}{\numberline {4.7.1}Strengths of the SLIPT Methodology}{175}{subsection.4.7.1}
\contentsline {subsection}{\numberline {4.7.2}Syntheic Lethal Pathways for E-cadherin}{176}{subsection.4.7.2}
\contentsline {subsection}{\numberline {4.7.3}Replication and Validation}{178}{subsection.4.7.3}
\contentsline {subsubsection}{\numberline {4.7.3.1}Integration with siRNA Screening}{178}{subsubsection.4.7.3.1}
\contentsline {subsubsection}{\numberline {4.7.3.2}Replication across Tissues and Cell lines}{179}{subsubsection.4.7.3.2}
\contentsline {section}{\numberline {4.8}Summary}{180}{section.4.8}
\contentsline {paragraph}{Aims}{182}{section*.41}
\contentsline {paragraph}{Summary}{182}{section*.42}
\contentsline {chapter}{\numberline {7}Discussion}{225}{chapter.7}
\contentsline {paragraph}{Aims}{225}{section*.130}
\contentsline {paragraph}{Summary}{225}{section*.131}
\contentsline {section}{\numberline {7.1}Significance}{227}{section.7.1}
\contentsline {section}{\numberline {7.2}Future Directions}{228}{section.7.2}
\contentsline {section}{\numberline {7.3}Conclusion}{229}{section.7.3}
\contentsline {chapter}{\numberline {8}Conclusion}{231}{chapter.8}
\contentsline {chapter}{\hbox to\@tempdima {\hfil }References}{232}{section*.42}
\contentsline {chapter}{\numberline {A}Sample Quality}{258}{appendix.A}
\contentsline {section}{\numberline {A.1}Sample Correlation}{258}{section.A.1}
\contentsline {section}{\numberline {A.2}Replicate Samples in TCGA Breast}{261}{section.A.2}
\contentsline {chapter}{\numberline {B}Software Used for Thesis}{265}{appendix.B}
\contentsline {chapter}{\numberline {C}Secondary Screen Data}{274}{appendix.C}
\contentsline {chapter}{\numberline {D}Mutation Analysis in Breast Cancer}{276}{appendix.D}
\contentsline {section}{\numberline {D.1}Synthetic Lethal Genes and Pathways}{276}{section.D.1}
\contentsline {section}{\numberline {D.2}Synthetic Lethal Expression Profiles}{279}{section.D.2}
\contentsline {section}{\numberline {D.3}Comparison to Primary Screen}{282}{section.D.3}
\contentsline {subsection}{\numberline {D.3.1}Resampling Analysis}{284}{subsection.D.3.1}
\contentsline {section}{\numberline {D.4}Compare SLIPT genes}{286}{section.D.4}
\contentsline {section}{\numberline {D.5}Metagene Analysis}{288}{section.D.5}
\contentsline {section}{\numberline {D.6}Mutation Variation}{289}{section.D.6}
\contentsline {subsection}{\numberline {D.6.1}Mutation Frequency}{289}{subsection.D.6.1}
\contentsline {subsection}{\numberline {D.6.2}PI3K Mutation Expression}{290}{subsection.D.6.2}
\contentsline {chapter}{\numberline {E}Metagene Expression Profiles}{293}{appendix.E}
\contentsline {chapter}{\numberline {F}Stomach Expression Analysis}{299}{appendix.F}
\contentsline {section}{\numberline {F.1}Synthetic Lethal Genes and Pathways}{299}{section.F.1}
\contentsline {section}{\numberline {F.2}Comparison to Primary Screen}{302}{section.F.2}
\contentsline {subsection}{\numberline {F.2.1}Resampling Analysis}{304}{subsection.F.2.1}
\contentsline {section}{\numberline {F.3}Metagene Analysis}{306}{section.F.3}
\contentsline {chapter}{\numberline {G}Stomach Mutation Analysis}{307}{appendix.G}
\contentsline {section}{\numberline {G.1}Synthetic Lethal Genes and Pathways}{307}{section.G.1}
\contentsline {section}{\numberline {G.2}Synthetic Lethal Expression Profiles}{310}{section.G.2}
\contentsline {section}{\numberline {G.3}Comparison to Primary Screen}{313}{section.G.3}
\contentsline {subsection}{\numberline {G.3.1}Resampling Analysis}{315}{subsection.G.3.1}
\contentsline {section}{\numberline {G.4}Metagene Analysis}{317}{section.G.4}
\contentsline {chapter}{\numberline {H}Global Synthetic Lethality in Stomach Cancer}{318}{appendix.H}
\contentsline {section}{\numberline {H.1}Hub Genes}{320}{section.H.1}
\contentsline {section}{\numberline {H.2}Hub Pathways}{321}{section.H.2}
\contentsline {chapter}{\numberline {I}Replication in cell line encyclopaedia}{322}{appendix.I}
